Thierry L.
- Country
- France
- Department
- Rheumatology
Research Overview
- A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active-Comparator Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a stable background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)
- Randomized Controlled Trial Comparing Methotrexate or Leflunomide with Targeted Therapy Versus Triple Therapy in Rheumatoid Arthritis Patients Unresponsive to Methotrexate or Leflunomide
Data & Insights
Has run more than one trial at 3 of 54 partner sites.
Specializations
Rheumatoid Arthritis Management
This investigator specializes in the treatment of rheumatoid arthritis, with particular emphasis on developing therapeutic strategies for patients with inadequate response to conventional treatments.
- Conventional DMARD Therapy
- Targeted Therapy Approaches
- Combination Treatment Strategies
The investigator explores treatment options including methotrexate, leflunomide, and triple therapy combinations.
Advanced Therapeutics
The investigator focuses on evaluating targeted therapeutic agents for moderate to severe rheumatoid arthritis, particularly in patients who have experienced treatment failures.
- JAK Inhibitor Studies
- TNF Inhibitor Therapeutics
- Biologic Response Assessment
Research interests include comparative studies of novel therapeutic agents against established treatments in rheumatoid arthritis.
Treatment Resistance
The investigator studies therapeutic approaches for treatment-resistant rheumatoid arthritis, specifically focusing on patients with inadequate response to conventional therapies.
- Alternative Treatment Pathways
- Sequential Therapy Strategies
- Treatment Optimization Methods
Special attention is given to developing solutions for patients with insufficient response to standard treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.